Tag: ITY WEU EUR NJY UNE USA NAM

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsITY WEU EUR NJY UNE USA NAM

PUDO Inc announces earnings call for Q1 FY 2026 – save the date

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

Tag: ITY WEU EUR NJY UNE USA NAM

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us